Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906469 | 0.90 | PDE4B (0.45) | PDE4BCNR1PPARAPDE4APDE4C | |
| SCHEMBL4633677 | 0.86 | PDE4B (0.52) | PDE4BCNR1PDE4APDE4CPDE4D | |
| SCHEMBL4634312 | 0.85 | CNR1 (0.53) | PDE4BCNR1PDE4APDE4CPDE4D | |
| SCHEMBL700719 | 0.85 | CNR1 (0.58) | PDE4BCNR1CNR2 | |
| SCHEMBL4910813 | 0.84 | PDE4B (0.54) | PDE4BCNR1PPARAPDE4APDE4C | |
| SCHEMBL4611618 | 0.82 | PDE4B (0.47) | PDE4BCNR1PDE4APDE4CPDE4D | |
| SCHEMBL4632911 | 0.81 | MAPT (0.53) | PDE4BCNR1PDE4APDE4CPDE4D | |
| SCHEMBL4632339 | 0.80 | CA9 (0.56) | PDE4BCNR1PDE4APDE4CPDE4D | |
| SCHEMBL3086689 | 0.79 | CNR2 (0.58) | CNR1PPARACNR2 | |
| SCHEMBL4634322 | 0.78 | PDE4B (0.47) | PDE4BCNR1PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146614-A1 | Therapeutic Agents | BDNF, NLN, GRIN2C | PDE4B 1199/4885CNR1 597/4885PPARA 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.